drugset / Trial / NCT07532330

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo

NCT07532330

Active not recruiting 67 enrolled Minia University
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations. The main questions it aims to answer are: Which combination (UVB + tacrolimus or UVB + tyrosine) leads to greater skin repigmentation (color return) after 3 months of treatment? What side effects do participants experience with each combination? Researchers will compare three groups: UVB + tacrolimus, UVB + tyrosine, and UVB only to see which is more effective and safer. Participants will: Receive narrowband UVB phototherapy sessions two times per week at minimal erythema dose Apply either topical tacrolimus or topical tyrosine to their vitiligo patches twice daily Visit the clinic every one month for skin examination and photography Report any side effects or skin reactions

Timeline

Start
2025-08-01
Primary completion
2026-02-19
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.1 % Topical
Subject tyrosine Unknown 2 % Topical

Indications